Terns Pharmaceuticals Inc Ordinary Shares TERN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Terns Announces Pricing of Upsized $150.15 Million Public Offering
-
Terns Pharmaceuticals' stock soars 17% after biotech posts positive results in trial of weight-loss drug in pill form
-
Terns Announces Proposed Public Offering
-
Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
-
Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates
-
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
-
Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
-
Mizuho still recommends Terns Pharma as a cheap entry to the weight-loss-drug craze
Trading Information
- Previous Close Price
- $8.85
- Day Range
- $8.51–8.98
- 52-Week Range
- $3.26–11.40
- Bid/Ask
- $8.47 / $8.69
- Market Cap
- $721.93 Mil
- Volume/Avg
- 1.4 Mil / 1.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 66
- Website
- https://www.ternspharma.com
Comparables
Valuation
|
Metric
|
TERN
|
EWTX
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.75 | 4.79 | 1.74 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
TERN
EWTX
PLRX
Financial Strength
|
Metric
|
TERN
|
EWTX
|
PLRX
|
|---|---|---|---|
Quick Ratio | 20.57 | 29.79 | 14.21 |
Current Ratio | 21.02 | 30.24 | 14.47 |
Interest Coverage | — | — | −106.49 |
Quick Ratio
TERN
EWTX
PLRX
Profitability
|
Metric
|
TERN
|
EWTX
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −28.87% | −23.23% | −27.65% |
Return on Equity (Normalized) | −30.36% | −24.43% | −31.11% |
Return on Invested Capital (Normalized) | −34.37% | −29.19% | −33.69% |
Return on Assets
TERN
EWTX
PLRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Lskwwktkp | Mjdm | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Vwrjzslsj | Xcjdb | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fqddpkfhb | Fynlb | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Msqpjfrn | Fwkvqdf | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Wnsvzts | Xxkk | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Yzbdtcbmd | Grf | $28.1 Bil | |||
| Moderna Inc
MRNA
| Xhylgwbpt | Nwgdh | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Klkkdvkn | Xfw | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bxfsvrqhx | Zzhttt | $13.4 Bil | |||
| Incyte Corp
INCY
| Qqzttbbk | Yqhdmcy | $12.7 Bil |
United States